Immunic Inc SEC Filings

IMMUNIC, INC. filed an initial Form 3 ownership report for Chief Executive Officer Erik Lundgren. The filing lists him as an officer of the company but does not report any specific share or option holdings and shows no purchases, sales, or other insider transactions. This is a baseline disclosure establishing his status as a reporting person for future ownership and trading reports.

Immunic, Inc. is asking stockholders to approve an amendment to its 2019 Omnibus Equity Incentive Plan to increase the shares authorized for issuance by 6,000,000 shares, bringing the total plan reserve to 8,644,887 shares. This is part of a broader effort to offset dilution from prior financings and maintain competitive equity incentives.

The company will hold a completely virtual annual meeting on June 29, 2026, with holders of 13,621,483 shares of common stock outstanding as of May 26, 2026 eligible to vote. Proposals include electing three Class III directors, approving the equity plan amendment, and ratifying Baker Tilly US, LLP as auditor for 2026.

Immunic discloses that, assuming approval of the plan amendment and exercise of all pre-funded warrants, total potential dilution from equity awards and pre-funded warrants would be approximately 22.2%. The compensation committee has already approved 1,950,819 contingent stock option grants at an exercise price of $11.60 per share, which will only become effective if stockholders approve the plan amendment.

Immunic, Inc. filed a current report describing new clinical data it is presenting from the phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis at the 2026 CMSC meeting. The company issued a press release and posted three posters covering efficacy methodology, patient-reported outcomes and safety.

A late-breaking poster introduces a unified Confirmed Disability Change endpoint that combines confirmed disability worsening and improvement; across three statistical models, results favored vidofludimus calcium over placebo. Another poster shows similar changes in depressive-symptom scores between groups through 120 weeks, with numerically higher patient-reported treatment effectiveness for vidofludimus calcium.

Safety data from 467 patients treated up to 120 weeks show comparable overall adverse event, discontinuation and serious adverse event rates between vidofludimus calcium and placebo, supporting a favorable tolerability profile. Vidofludimus calcium remains an investigational oral therapy in late-stage trials for multiple sclerosis.

Immunic, Inc. has appointed biopharmaceutical executive Erik Lundgren as Chief Executive Officer effective May 22, 2026, with employment beginning June 1, 2026, succeeding Daniel Vitt, Ph.D., who remains on the Board and continues to lead scientific strategy and portfolio advancement.

Lundgren’s employment agreement provides a yearly base salary of $685,000, eligibility for a yearly bonus of at least 60% of base salary, and a guaranteed full-year 2026 bonus at not less than that level, paid in six monthly installments of $68,500 each. He may receive an additional $200,000 cash bonus if the pending phase 3 trial for relapsing multiple sclerosis supports a New Drug Application and he remains employed through March 31, 2027, plus a separate $250,000 cash bonus within one month of the effective date.

Severance protections include lump-sum payments and equity vesting enhancements if he is terminated without cause, resigns for Good Reason, or is not renewed, with richer benefits during a Change of Control Period. The Compensation Committee also granted Lundgren an option to purchase 1,000,000 shares of common stock under the 2026 Inducement Equity Compensation Plan, with 25% vesting on the one-year anniversary of May 22, 2026 and the remainder vesting monthly over 36 months at an exercise price equal to the closing stock price on the approval date.

IMMUNIC, INC. filed an initial insider ownership report for director Michael W. Bonney on Form 3. This filing identifies him as a director of the company but does not list any stock or option transactions, and shows no reported holdings or derivative positions at this time.

Immunic, Inc. appointed Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026. Bonney brings more than three decades of biopharmaceutical leadership, including CEO experience at Cubist Pharmaceuticals and senior commercial roles involved in launching Avonex for multiple sclerosis.

In connection with his appointment, he received options to purchase up to 100,000 shares of Immunic common stock, vesting monthly over three years at an exercise price equal to the May 15, 2026 Nasdaq closing price, subject to shareholder approval of an increase in the 2019 Omnibus Equity Incentive Plan share reserve. Simona Skerjanec will transition from Interim Chairperson to continue as a director, and the Board size increases from nine to ten members. Immunic highlights its late-stage program vidofludimus calcium, currently in phase 3 trials in relapsing multiple sclerosis, with top-line data expected by the end of 2026.

Immunic, Inc. reports that Alyeska-affiliated reporting persons beneficially own 6,332,000 shares of Common Stock, representing 4.85% of the class. The stake, reported as of March 31, 2026, includes 4,041,000 shares issuable upon exercise of warrants and 2,291,000 shares issuable upon exercise of pre-funded warrants. The filing shows shared voting and dispositive power over the 6,332,000 shares. The number of shares outstanding is listed as 130,464,825 per the Form S-3 dated April 2, 2026.

IMMUNIC, INC. files an Amendment No. 2 to a Schedule 13G/A noting an "exit filing" by certain reporting persons. The amendment states that, as of May 15, 2026, 683 Capital Partners, LP, 683 Capital Management, LLC and Ari Zweiman may be deemed to beneficially own 474,200 shares (including 229,200 exercisable warrants), representing 3.4% of the company's common stock. The filing cites 13,621,526 shares outstanding as of April 28, 2026 as the base for the percentage calculation and includes the verbatim comment that the Reporting Persons "no longer beneficially own more than five percent" of the issuer.

Immunic, Inc. reported first quarter 2026 results and highlighted a large private financing to fund its multiple sclerosis programs. For the three months ended March 31, 2026, the company recorded a net loss of $32,588 thousand, driven by research and development expenses of $25,626 thousand and general and administrative expenses of $7,609 thousand.

In February, Immunic closed an oversubscribed private placement of up to $400 million in gross proceeds, with $200 million received upfront, which management expects to fund operations through completion of the phase 3 ENSURE trials in relapsing multiple sclerosis and a planned RMS New Drug Application submission in mid-2027. Cash and cash equivalents increased to $186,629 thousand as of March 31, 2026, and total stockholders’ equity improved to $151,233 thousand, reflecting the new capital despite ongoing operating losses.